All In Biotech

Drug Trial Radar · NCT05819684

A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors

A Phase I Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4602 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

Last checked: Nov 19, 2026Latest source record: Jun 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

133

Planned (sponsor's estimate)

Start

Apr 18, 2023

Primary completion

May 30, 2025

Study completion May 30, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

Conditions

  • Advanced Solid Tumor

Interventions

  • SHR-4602 for injectionDrug

    be administered via intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs)Time frame: From Day 1 to 90 days after last dose
  2. Maximum tolerated dose (MTD)Time frame: From Day 1 to 21 days after first dose
  3. Dose Limiting Toxicities (DLT)Time frame: From Day 1 to 21 days after first dose
  4. Recommended Phase 2 dose (RP2D)Time frame: From Day 1 to 90 days after last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.